The Chlortetracycline/Decoquinate combination is a specialized therapeutic product used to manage conditions driven by dual microbial challenges and is relevant for easing distressing manifestations associated with susceptible bacteria and coccidial protozoa.

Dual Management of Infectious Enteritis and Respiratory Illness

This domain may assist with managing acute diseases caused by bacteria, such as bacterial enteritis and bacterial pneumonia, and it is relevant for addressing the bacterial component of the Shipping Fever Complex. Furthermore, the combination is commonly used to help with the long-term risk reduction provided by the Decoquinate component, particularly against Coccidiosis when it is likely to be a hazard.

This approach provides support that helps ease the overall burden of acute, disruptive manifestations, especially in young or growing animals. It contributes to improved comfort by aiming to reduce the risk of severe intestinal damage associated with infection and supports maintaining functional stability during high-stress periods.

“Applied in clinical settings that involve acute or unstable symptom patterns, the product helps manage symptoms that interfere with daily functioning.”

---

Quick Fact: Relief for Gastrointestinal Distress The medicine is commonly used to help with acute diarrhea and systemic discomfort caused by bacterial infections and protozoal infestations, and supports patients during episodes of heightened discomfort.

Regulatory References

1. FDA Freedom of Information Summary

Eligibility for Chloromax / Deccox Use

Official regulatory eligibility for the Chlortetracycline/Decoquinate combination is strictly defined by the target species, production class, and physiological status of the animal. This medicine is primarily approved for specific non-producing animal populations and certain poultry classes, often requiring a Veterinary Feed Directive (VFD) from a licensed veterinarian.

---

Absolute Prohibitions (Contraindications)

Use is strictly contraindicated in animal populations where the drug residue could enter the human food supply. This includes:

• Animals producing milk for human consumption (e.g., lactating dairy cattle).
• Chickens or turkeys producing eggs for human consumption.
• Calves to be processed for veal.
• Animals with known hypersensitivity to Chlortetracycline or Decoquinate.

---

Permitted and Restricted Populations

The product is allowed for use in calves, beef cattle, non-lactating dairy cattle, broiler chickens, and replacement chickens. Restrictions apply to the animal's internal health; for instance, the medicine is not recommended for animals with severe liver and renal disorders or those with functional rumens. Furthermore, a withdrawal period has not been established for pre-ruminating calves, which restricts its use in this class.

The official interaction profile for the Chloromax / Deccox combination product is primarily defined by specific physicochemical and pharmacokinetic restrictions related to its administration as a medicated feed premix. This profile is structured around exposure-modifying interactions and administrative prohibitions documented in regulatory labels.

Documented Exposure-Modifying Interactions

Interacting Substance/Category	Official Interaction Classification
Divalent and Trivalent Cations (e.g., Calcium, Iron)	Exposure-Reducing Pharmacokinetic Interaction

This officially documented interaction is a result of chelation, where polyvalent cations, commonly found in feed and water, bind to the Chlortetracycline component. This binding prevents adequate release and absorption of the antibiotic, leading to a substantial reduction in systemic exposure.

Regulatory-Defined Restrictions and Rules

To mitigate the exposure-reducing effect of chelation, official regulatory documents define a mandatory administrative rule regarding feed content. This rule requires the medicated feed premix to be administered using feeds with specified low-calcium concentrations to ensure the maintenance of drug exposure as established by the regulator. Furthermore, an administrative prohibition is defined where the co-administration of the Decoquinate component with feed containing high levels of bentonite is not permitted.

The overall regulatory structure emphasizes the critical need to adhere to these mandated content rules. This strictly defined drug-substance interaction dictates the official parameters for administration to ensure that the systemic exposure of the active components remains within the documented range.

The combined effect of this product is rooted in two independent, targeted forms of inhibition against pathogens. Chlortetracycline acts by binding reversibly to the bacterial 30S ribosomal subunit, blocking the aminoacyl-tRNA access site. This key molecular action halts protein synthesis in susceptible bacteria, leading to a bacteriostatic effect and reduction in bacterial proliferation.

Simultaneously, Decoquinate specifically targets the energy metabolism of protozoa (coccidia). Decoquinate competitively inhibits the parasite's mitochondrial cytochrome bc₁ complex at the Qo site. This blocks the electron transport chain, which results in the rapid cessation of ATP generation and causes the parasitic death of the early developmental stages. This mechanism limits parasitic development and the subsequent capacity for tissue invasion.

These two distinct mechanisms provide functional complementarity by addressing bacterial mechanisms and protozoal mechanisms concurrently, contributing to the limitation of simultaneous proliferation of both pathogen types within the host.

The Chlortetracycline/Decoquinate combination product is administered orally, typically incorporated as a Type C Medicated Feed or top-dress supplement. Administration of this product is governed by a Veterinary Feed Directive (VFD) and must only proceed on the order of a licensed veterinarian.

Administration Regimen and Dosing

The standard regimen dictates that the product be administered once daily, with the dose calculated based on the animal’s body weight. The required daily intake is 1 gram of Chlortetracycline (CTC) and 22.7 milligrams of Decoquinate (DEQ) per 100 pounds of body weight.

Usage involves a sequential course duration. The Chlortetracycline component is restricted to a maximum of 5 consecutive days of administration. Following or concurrent with this initial phase, the Decoquinate component must be continued to ensure a total administration period of at least 28 days for the anticoccidial component.

Population and Preparation Rules

The use of this product is limited to calves, beef cattle, and non-lactating dairy cattle. Use is explicitly prohibited for calves intended to be processed for veal, as well as for animals producing milk for human food. During feed preparation, specific formulation rules must be followed, including the instruction that the material bentonite should not be used in the manufacture of feeds containing Decoquinate.

Evidence for the Prevention of Coccidiosis

Research explored the product's use in the prevention of protozoal infection in young animals using controlled field studies. These studies examined outcomes related to physical discomfort and parasite load, such as oocyst shedding and clinical signs. Follow-up durations were typically intermediate-term, lasting a minimum of 28 days, which coincided with the medication period. Findings describe patterns observed in the studies where animals had patterns related to oocyst shedding metrics. However, this research is primarily derived from non-human animal models and specific field settings, and long-term outcomes are not well characterized.

---

Studies on Bacterial Enteritis and Pneumonia

Research explored the product's use in conditions associated with acute episodes, specifically bacterial enteritis and bacterial pneumonia. Controlled clinical trials evaluated the product in high-risk populations, such as calves and young cattle, tracking survival rates and metrics defined by clinical outcomes. Large-scale Randomized Controlled Trials (RCTs) in high-stress populations examined rates of illness related to breathing and re-treatment. Limited contemporary peer-reviewed analyses are available for enteritis, and for pneumonia, the isolated, independent contribution of the product was observed in some studies to be limited by the simultaneous use of other health interventions.

---

Research on Performance and General Health Metrics

Research on performance was evaluated in large-scale field RCTs and observational studies to examine overall performance metrics like Average Daily Gain (ADG). These trials included feeder steers and calves with long-term follow-up. Findings describe patterns observed in the studies where performance metrics were associated with effective management of disease burden. The isolated, direct impact on growth is not fully established separate from its role in influencing disease.

---

Long-Term Studies and Follow-up Duration

The length of observation varies, with some performance studies extending follow-up durations to the full feeding phase. However, the research provides limited information for long-term outcomes regarding the durability of the effect or patterns of use beyond the initial periods. Long-term effects are not fully established across all populations, and research is ongoing.

---

Evidence in Studied Populations

The primary research base was observed in specific veterinary populations: calves, beef cattle, and feeder steers. Results apply only to the populations studied, meaning the evidence is focused on these specific age and health status groups. Subgroup data remain insufficient beyond the high-risk, feeder cattle population.

---

What Remains Uncertain About Chloromax / Deccox Research

It is not yet clear whether the precise, isolated contribution of each component is well-defined within the combination product. Furthermore, comparative evidence is lacking against all modern, single-agent therapies. Evidence quality varies across studies, reinforcing that research is an ongoing process.

Key Studies & References

1. FDA Freedom of Information Summary for NADA 036-749 (Chlortetracycline and Decoquinate Medicated Article)
2. Tetracyclines family in IUPHAR/BPS Guide to PHARMACOLOGY (Used for classification and origin context)

Common questions about Chloromax / Deccox (FAQ)

---

Q: Are there any known interactions between Deccox and other common feed ingredients?

Regulatory documents state that the material bentonite is not permitted in feeds containing Decoquinate. This rule is in place to support the maintenance of drug exposure. Studies examining the drug's use suggest that no other practically relevant interactions exist with common feed additives or other general veterinary drugs.

---

Q: Are there any warnings regarding mixing this product with other anticoccidial drugs?

Official regulatory documents do not specify any other practically relevant interaction warnings regarding co-administration with other anticoccidial drugs. The primary restriction noted is the mandatory avoidance of feed containing bentonite, which is related to supporting the drug's effectiveness.

---

Q: Can this product be used in very young or newborn animals?

The product is approved for use in calves, which includes those that are non-ruminating (meaning they are still receiving whole milk or milk replacer). However, official labeling strictly prohibits its use in calves intended to be processed for veal.

---

Q: Can the active ingredient affect the health of animals in the long term?

The Decoquinate component supports normal growth when an animal is challenged by parasites but is not shown to improve the growth of healthy animals. Official labeling for the chlortetracycline component notes prolonged or repeated use as being associated with a risk factor for the development of antibiotic resistance.

---

Q: Is it typical for animals not to show any outward symptoms when the product is working?

The medicine is indicated for the control of subclinical coccidiosis, which involves addressing infection before obvious outward sickness occurs. Research has observed that the medicine's use is successful when it helps maintain normal growth under parasite challenge, and a lack of clinical signs is consistent with the drug fulfilling its preventive function.

---

Q: What happens if an animal accidentally consumes a higher concentration of the product?

Regulatory tolerance studies indicate that Decoquinate has a wide safety margin. Dosages up to 5 to 10 times the recommended amount have been found to be well tolerated and without observable side effects in the target animal species, according to official information.

---

Q: Is Chloromax / Deccox safe to use in pregnant or lactating animals?

Official labeling for the Decoquinate component confirms that it can be used during pregnancy. However, the combination product is explicitly prohibited for use in lactating dairy cattle. This prohibition is in place due to the mandated requirement to prevent drug residue transfer into milk intended for human consumption.

---

Q: Is the medication effective against all known types of coccidia parasites?

Regulatory documents specify the product is approved and effective against certain types of Eimeria parasites, such as Eimeria bovis and Eimeria zuernii in cattle. The official documentation only provides statements of effectiveness for these specific types of coccidia.

---

Q: Is it safe for the people handling the product during feed preparation?

Safety documentation indicates the active ingredients have low toxicity. Precautions for personnel handling the premix require working in a well-ventilated area, avoiding the generation and inhalation of dust, and washing hands after use.

---

Q: What is the scientific mechanism by which Decoquinate interferes with the parasite's lifecycle?

The scientific mechanism involves Decoquinate inhibiting the parasite's mitochondrial cytochrome bc₁ complex. This action disrupts the parasite's energy production by blocking the electron transport chain, which rapidly stops the necessary creation of ATP and causes parasitic death during its early developmental stages.

---

Q: Are there any known environmental risks associated with using this product in livestock?

Environmental risk assessments performed for the product indicate that the predicted concentrations of the drug in soil, sediment, and water are below regulatory safety thresholds. Environmental assessments indicate that the predicted concentrations are below regulatory safety thresholds for these compartments, based on use according to official directions.

---

Q: How is the product described in European Union (EMA) documents?

European Union-based documentation (VMD/Defra) describes the Decoquinate product as a Premix for Medicated Feeding Stuff. It is indicated for the treatment and prevention of coccidiosis and sometimes for preventing losses due to toxoplasmosis in ewes.

---

Q: Does the product's safety margin allow for small variations in feeding accuracy?

Regulatory studies have established a wide safety margin (a therapeutic index of 5 to 10) for Decoquinate. The wide safety margin documented is consistent with tolerance for minor variations in feed concentration, compared to the exact recommended amount.

How to Store and Dispose of Chloromax / Deccox

Official regulatory documents define strict storage requirements for the Decoquinate/Chlortetracycline premix to maintain its quality.

Requirement	Official Regulatory Statement
Temperature	Store product below 25°C (77°F); avoid excessive heat.
Protection	Keep in a dry place, away from direct sunlight and ignition sources.
Packaging	Keep the container tightly closed to avoid contamination.
Stability	Shelf-life is 3 years as packaged, reduced to 3 months when mixed into final feed.
Safety	Mandatory requirement to keep out of reach of children.

Disposal instructions state that the material must not enter surface water drains or waterways. Appropriate procedural waste measures must be implemented to prevent environmental releases of the unused product.